News | January 29, 2013

New Test May Reduce Time in Diagnosing Heart Attacks, Assist in Determining Risk for Future MI

Abbot Vascualr Architect Stat Blood Testing Point-of-Care Testing

January 29, 2013 — An estimated 17 million people throughout the world die annually of cardiovascular diseases, specifically heart attacks or strokes.[1] Time is a critical factor in diagnosing and treating people who may be having a potential heart attack. To aid physicians in detecting heart attacks sooner, Abbott announced CE marking (Conformite Europeenne) for the Architect Stat High Sensitive Troponin-I Assay.

Diagnosing Potential Heart Attacks

The preferred biomarker used to identify suspected heart attacks is cardiac troponin, a protein found in the heart muscle, because it can detect injury to the heart.[2] Many patients who visit the emergency room with chest pain complaints and a suspected heart attack currently have blood samples drawn for troponin tests upon admission, after 6 hours, and then potentially 12 hours later before a diagnosis may be made.[3] For patients who are having a heart attack, the length of time to diagnosis is a crucial factor because the heart muscle cells start to die after the heart stops receiving blood, and eventually, almost all the affected parts of the heart could be irreversibly damaged.  

Abbott's new Architect Stat High Sensitive Troponin-I Assay can measure very low levels of the protein, which allows doctors to evaluate whether or not patients are having a heart attack within two to four hours.[4] This faster evaluation could allow doctors to reduce the time to diagnosis and treatment by several hours when compared to standard troponin tests.

"The advantage of high sensitive troponin tests compared to current tests is that clinicians may now more precisely confirm or exclude a heart attack much sooner and with higher accuracy compared to contemporary tests," said Professor Stefan Blankenberg, director of cardiology at the University Heart Center of Hamburg, Germany. "This is important information for patient care because we can pursue treatment if needed or avoid invasive therapy and discharge a patient earlier."

Determining Risk for Future Cardiovascular Events

Another concern for patients who have experienced symptoms of a heart attack or who suffered from an actual attack is that they are at a higher risk for experiencing a second cardiac event or heart attack within a few weeks or months. Abbott's High Sensitive Troponin-I Assay also enables doctors to determine if patients are at risk to suffer from cardiovascular events 30 days and 90 days later.

"The sooner a patient can be diagnosed with a cardiac event, the faster a patient can get the care he or she needs," said Brian Blaser, executive vice president, Diagnostics Products, Abbott. "Abbott's new high sensitive troponin test is an innovative tool to help physicians diagnose more quickly, potentially improving the way heart attacks are diagnosed for patients around the world."

The new assay runs on Abbott's fully-automated Achitect family of analyzers and is available in CE marked and non-regulated countries, pending country registration.

Intended Use

The Architect Stat High Sensitive Troponin-I assay is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of cardiac troponin I (cTnI) in human plasma and serum on the Architect i System with STAT protocol capability. The cTnI values are used as an aid in the diagnosis of myocardial infarction (MI) and to aid in the assessment of 30-day and 90-day prognosis relative to all-cause mortality and major adverse cardiac events (MACE) consisting of myocardial infarction, revascularization, and cardiac death in patients who present with symptoms suggestive of acute coronary syndrome (ACS).

For more information: www.abbott.com

 

References:

1. Cardiovascular Diseases Fact Sheet No 317. World Health Organization, September 2012. Web site:www.who.int/mediacentre/factsheets/fs317.

2. Thygesen K, Alpert JS, Jaffe AS et al. Third universal definition of myocardial infarction. European Heart Journal. 2012; 33:2551-2567.

3. Thygesen K, Alpert JS, White HD et al.  Universal definition of myocardial infarction. European Heart Journal. 2007; 28:2525-38.

4. Abbott ARCHITECT STAT High Sensitive Troponin-I Product Insert (PI), January 2013.

5. Cardiovascular Diseases Fact Sheet No 317. World Health Organization, September 2012. Web site:www.who.int/mediacentre/factsheets/fs317.


Related Content

Technology | Blood Testing

October 9, 2019 — Abbott recently announced that its Architect Stat High Sensitivity Troponin-I blood test has received ...

Home October 09, 2019
Home
News | Blood Testing

September 18, 2019 — Discharge of patients with suspected acute coronary syndromes under a 0- and 1-hour high ...

Home September 18, 2019
Home
News | Blood Testing

March 19, 2019 — Prevencio Inc. announced data confirming the high accuracy of its artificial intelligence (AI)-driven ...

Home March 19, 2019
Home
News | Blood Testing

December 28, 2018 —Terrific Care LLC. / Medex Supply Dist Inc. initiated a nationwide recall on Dec. 19 of Roche ...

Home December 28, 2018
Home
News | Blood Testing

October 26, 2018 — For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians ...

Home October 26, 2018
Home
News | Blood Testing

October 24, 2018 — For those living with diabetes, monitoring blood glucose accurately is necessary to prevent diabetes ...

Home October 24, 2018
Home
News | Blood Testing

October 16, 2018 — Abbott announced that its High Sensitive Troponin-I blood test has received CE Mark for distribution ...

Home October 16, 2018
Home
News | Blood Testing

September 4, 2018 — Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral ...

Home September 04, 2018
Home
News | Blood Testing

August 6, 2018 — A new test to assess a whether or not someone is having a heart attack upon arriving in the emergency ...

Home August 06, 2018
Home
News | Blood Testing

March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singulex ...

Home March 26, 2018
Home
Subscribe Now